Gene therapy utilizing drug resistance genes: a review.
The generation of drug resistant bone marrow may facilitate the development of aggressive chemotherapeutic regimens that might otherwise be lethal due to marrow toxicity. With the availability of technology that permits in vitro manipulation of human marrow and peripheral blood stem cells, it is now possible to introduce genes that confer drug resistance to these hematopoietic progenitors. Animal models and in vitro work with human progenitors using drug resistance genes are reviewed.
Molecular Pharmacology and Therapeutics Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
D
D
Banerjee
S C
SC
Zhao
M X
MX
Li
B I
BI
Schweitzer
S
S
Mineishi
J R
JR
Bertino
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001854:Bone Marrow Cells; D016466:CHO Cells; D006224:Cricetinae; D004285:Dogs; D004351:Drug Resistance / Q000235:genetics*; D015316:Genetic Therapy; D005822:Genetic Vectors; D000882:Haplorhini; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D006801:Humans; D051379:Mice; D013762:Tetrahydrofolate Dehydrogenase / Q000235:genetics
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000970:Antineoplastic Agents; D013762:Tetrahydrofolate Dehydrogenase